Background and Aims: Adherent invasive Escherichia coli [AIEC] are abnormally predominant on the ileal mucosa of Crohn's disease [CD] patients. They bind to the CEACAM6 receptor expressed on the surface of epithelial cells. We aimed to assess the potential of bacteriophages, viruses infecting bacteria, to decrease the levels of AIEC bacteria associated with the intestinal mucosa. Methods: We combined ex vivo and in vivo experiments with murine and human intestinal samples to quantify the ability of virulent bacteriophages to target the prototype AIEC strain LF82. Results: We found that three virulent bacteriophages were able to replicate in ileal, caecal and colonic sections and faeces homogenates from murine gut samples colonised with the prototype AIEC strain LF82. A single day of per os treatment with the three bacteriophages cocktail given to LF82-colonised CEABAC10 transgenic mice, expressing the human CEACAM6 receptor for AIEC, decreased significantly the number of AIEC in faeces and in the adherent flora of intestinal sections. In addition, a single dose of the cocktail reduced dextran sodium sulphate-induced colitis symptoms on conventional mice colonised with the strain LF82 over a 2-week period. The cocktail targeted also LF82 bacteria in homogenates of ileal biopsies taken from CD patients.
Introduction
Inflammatory bowel diseases [IBD] , including Crohn's disease [CD] and ulcerative colitis [UC] , are chronic and relapsing, lifelong diseases of the gastrointestinal tract [GIT] . The precise cause of IBD is unknown, but this multifactorial disease is thought to result from the complex interplay between environmental factors and genetic susceptibility, resulting in an abnormal mucosal immune response. 1 Genetic studies of CD have uncovered new mechanisms involved in the pathogenesis of this disease, including defects of a biological process called autophagy [ATG16L1 and IRGM genes], innate mucosal defense [NOD2 gene], or endoplasmic reticulum stress [Xbp1 gene]. 2 The higher incidence of IBD in industrialised countries than in developing countries, in which the incidence of IBD is nevertheless increasing, clearly suggests that environmental factors make an important contribution to disease pathogenesis. 3 However, no strong environmental factors other than smoking and appendectomy have yet been identified for IBD. 4 The effects of diet have been studied in detail, but the findings of these studies have been inconsistent. However, an altered gut microbiota has long been suspected to play an important role in IBD pathogenesis. 5, 6 In this context, the frequent recovery of particular strains of Escherichia coli with adherent and invasive properties [adherentinvasive E. coli, AIEC] from the mucosa of CD patients has attracted considerable attention. These bacteria constitute a new pathovar of E. coli, lacking the type III secretion system and other classical virulence factors typically associated with pathogenic intestinal E. coli. 7 The prototype AIEC strain LF82 was isolated in 1998 from a chronic ileal lesion from a CD patient. 8 Strain LF82 has type 1 pili that can bind to the host adhesion receptor carcinoembryonic antigen-related cell adhesion molecule 6 [CEACAM6] , which is more strongly expressed in the ileal tissues of CD patients than in those of controls. 9 In transgenic CEABAC10 mice with high levels of expression of human CEACAMs, LF82 efficiently binds to epithelial cells and colonises gut mucosa in a type 1 pilus-dependent manner. 10 Several therapeutic strategies targeting AIEC colonisation have been proposed to slow or even halt the natural course of CD. Manipulation of the patient's microbiota through antibiotic treatment, faecal transplantation, nutritional interventions or the administration of pre/probiotics could be used either alone or in combination with immunotherapy, to induce the remission of active disease or as a postoperative treatment to prevent relapse. However, the results obtained to date have been disappointing. 11 Antibiotic treatments are becoming less effective, due to the increasing prevalence of multidrug resistance among bacteria, as highlighted by the World Health Organization. 12 Over the past 10 years, E. coli has acquired worryingly high levels of resistance to multiple antibiotics, with rapid dissemination worldwide as exemplified by the epidemic clonal complex E. coli ST131-O25b:H4 and more recently by the spread of plasmids carrying resistance to colistin [MCR-1], one of the last-resort antibiotics. 13, 14 Dissemination occurs mostly through the digestive tract carriage of E. coli strains by mammals, including humans travelling between countries. 15, 16 The human digestive tract is also an environment in which bacteria can exchange genetic material, including antibiotic resistance genes, and this has led to strong recommendations that antibiotics should not be used in a prophylactic manner. 17 An evaluation of non-conventional antibacterial treatments, such as those based on bacteriophages, is therefore required to deal with this major public health issue. Bacteriophages, viruses infecting bacteria, were discovered before antibiotics and have been used for many years in some countries [Georgia, Poland, Russia], in antibacterial treatments known as phage therapy. [18] [19] [20] Bacteriophages are omnipresent in the environment, including the human GIT in which they are at least as numerous as bacteria. 21, 22 Unlike antibiotics, they are highly specific, infecting only a limited number of strains within a given bacterial species, and have therefore,a much smaller impact on the composition of the microbiota. [23] [24] [25] In this study, we evaluated the potential of bacteriophages to decrease intestinal colonisation with AIEC bacteria, in wild-type and CEACAM6-expressing mice. Our results, demonstrating the high efficacy of bacteriophages in reducing intestinal colonisation of AIEC strain LF82, strongly support their clinical evaluation in CD patients. 
Materials and Methods

Bacteriophage isolation, preparation and characterisation
We isolated and purified several bacteriophages infecting strain LF82 from waste water, with an enrichment technique. 29 Since AIEC bacteria do not belong to a specific phylogenetic group or serotype, we performed host-range determination on the E. coli Collection of Reference [ECOR] , and selected three bacteriophages, LF82_P2, LF82_P6, and LF82_P8, showing complementary host ranges, and prepared large-scale solutions as previously described [see Supplementary Table S1 , available at ECCO-JCC online]. 29, 30 Bacteriophage titres were determined by spotting 4-µl drops of 10-fold serial dilutions onto LB agar plates covered with a lawn of strain LF82 or LF82SK. The three-bacteriophage cocktail contained equal numbers of each of the three bacteriophages, as indicated. These three bacteriophages are equally effective against strains LF82 and LF82SK and their genomes were sequenced with Illumina technology. For each genome, a single large contig was generated by reads assembly, and this contig was used to identify closely related bacteriophage genomes with the NCBI blastn tool [see Supplementary 6 pfu] was added to homogenates [200 µl], which were then incubated for 5 h at 37°C. We then spotted 10-fold serial dilutions of samples onto LB agar plates covered with a lawn of strain LF82SK for the counting of bacteriophages.
Bacteriophage treatment in CEABAC10 mice
We assessed the colonisation of the gut of CEABAC10 mice with LF82, using a modified version of the method described by Carvalho et al. 7 pfu per mouse twice on the same day, 7 h apart, in 200 µl of sterile 20% sucrose and 2.6% sodium bicarbonate, pH 8] by oral gavage. Fresh faecal samples were collected to assess the degree of colonisation with strain LF82. One or 4 days after phage administration, the mice were euthanised by cervical dislocation under isoflurane anaesthesia, for assessment of the numbers of LF82 bacteria associated with colonic or ileal tissues by direct and indirect methods, and for the determination of bacteriophage levels by the spotting of 10-fold serial dilutions onto LB agar plates covered with a lawn of strain LF82. Assessment of neutrophil influx was performed on 0. Table S3 , available at ECCO-JCC online], with no effect on mouse survival. We established this protocol from preliminary experiments in which we showed that: i] decreasing streptomycin concentration had no effect on the level of gut colonisation with LF82SK [assessed from faeces] for up to 3 weeks; and ii] 1% DSS did not induce major symptoms of colitis within 10 days, whereas 3% DSS had too strong an effect, resulting in the euthanasia of the animal within 3 days. We also found that, in the presence of 2% DSS, mild colitis symptoms appeared 7-9 days after gavage with LF82SK. Five or 7 days after the addition of 2% DSS to the drinking water, we administered the cocktail of bacteriophages [3 x 10 7 pfu per mouse] to the mice by oral gavage. Faecal pellets were collected at the indicated time points, for assessment of the levels of both LF82SK and bacteriophages. The mice were euthanised 25 days after the administration of the LF82SK strain, to assess LF82SK and bacteriophage levels in organs.
Quantification of bacteria and bacteriophages in colonised mice
Freshly collected faecal samples were weighed and homogenised in PBS [0.08 g/ml final concentration], serially diluted in PBS, and 4 µl of each dilution was spotted onto Drigalski agar supplemented with streptomycin and kanamycin for the quantification of strain LF82SK, or onto LB agar supplemented with ampicillin and erythromycin for the quantification of strain LF82. The plates were incubated for 18 h at 37°C. When necessary, ileal or colonic sections of intestine were collected in aseptic conditions, weighed, homogenised in PBS, and subjected to 10-fold serial dilution and plating, as described above. When indicated, the mice received 200 µl of the cocktail of bacteriophages containing a total of 3 x 10 7 pfu of bacteriophages. Bacteriophages were quantified by spotting 10-fold serial dilutions onto LB agar plates covered with a lawn of strain LF82 or LF82SK. The detection limit was 5 x 10 2 cfu/g or pfu/g of tissue or faeces.
For tissue homogenates and faeces, we found as previously reported, that direct counts of E. coli colonies were not accurate because of the abundance of bacteriophages, a problem that can be overcome by using an indirect method based on quantitative polymerase chain reaction [qPCR] . 31 
6 cfu], washed three times in sterile water to eliminate traces of growing medium, were added to two aliquots and incubated for 60 min at 37°C without shaking. Then, 25µl of the phage cocktail [1.8 x 10
4 pfu] were added to half of the samples that received strain LF82SK as well as the samples that did not receive it. Volumes were adjusted to 150 µl with PBS. The same conditions were applied to strain LF82 growing in LB as control. Bacteriophages were enumerated after 5 and 24 h of incubation at 37°C without shaking. 
Statistical analysis
Results
Bacteriophages infect AIEC in vitro and ex vivo in colonised sections of mouse gut
Bacteriophages were isolated from waste water and characterised in vitro [methods; see online Supplementary Table S1 ]. We selected three bacteriophages [LF82_P2, LF82_P6, and LF82_P8] that infected both AIEC strains LF82 and LF82SK [an antibiotic-resistant derivative of strain LF82], and sequenced them. Their sequences showed that they are different from each other and revealed their similarity to previously described virulent bacteriophages [see online Supplementary Table S2 ]. The ability of each bacteriophage to replicate in an intestinal environment was studied ex vivo in gut homogenates from the small and large intestines collected from LF82SK-colonised mice [ Figure 1 ]. 31 Bacteriophages LF82_P2 and LF82_P6 displayed similar profiles, with higher levels of amplification from ileal and colonic sections than from the caecum and faeces, whereas amplification levels for LF82_P8 were high and similar for all gut sections.
Bacteriophages reduce the colonisation of the gut by AIEC strain LF82 in transgenic mice expressing the human CEACAM6 glycoprotein
We then investigated the ability of a cocktail of these three bacteriophages [equal amounts of each bacteriophage] to infect adherent LF82 bacteria, in the CEABAC10 transgenic mouse model which expresses the human CEACAM6 receptor for AIEC bacteria. Figure 2A ]. Twenty-four h post treatment, the concentration of strain LF82 in faeces had fallen significantly, by two orders of magnitude, in the bacteriophage group. It remained significantly lower than that in the control group 4 days after treatment, without the administration of additional bacteriophages [ Figure 2B ]. Concomitantly we observed that the number of bacteriophages in faeces in the bacteriophage group decreases according to the concentration of strain LF82, whereas in the group of non-colonised mice it had fallen below the detection threshold within 24 h [ Figure 2C ]. These variations did not affect the weight of animals nor MPO levels in ileum and colon sections collected at Day 5 [see Supplementary Figure S1 , available at ECCO-JCC online].
We also analysed the adherent E. coli bacteria from ileal and colonic gut sections from both the bacteriophage and control groups, with a semi-quantitative real-time PCR method for bacterial quantification [the abundance of bacteriophages in samples has been shown to affect the accuracy of direct bacterial counts]. 31 Twenty-four h post treatment, the levels of the adherent strain LF82 [ Figure 3A ] were significantly lower in all the gut sections of the bacteriophage group than in those of the control group. Four days post treatment, the differences between the two groups remained significant other than for ileal sections [ Figure 3B ]. Thus, by direct and indirect methods, we showed that the administration of a bacteriophage cocktail on 1 day progressively reduced the level of LF82 colonisation of the entire GIT over the following 5 days, despite the expression of the CEACAM6 receptor for AIEC.
Bacteriophages reduce colitis symptoms in conventional mice colonised with AIEC strain LF82SK
We moved one step closer to clinical settings by investigating the relationship between the ability of bacteriophages to decrease colonisation by AIEC and the control of intestinal colitis symptoms induced by DSS in conventional mice, by determining DAI score [see Methods]. Three groups of mice colonised with strain LF82SK received three independent treatments [ Figure 4A ]. As a preliminary study showed that DAI score increased between 7 and 9 days after the administration of the LF82SK strain [see Methods], we investigated whether the administration of a single dose of the bacteriophage cocktail [ administration could affect colitis symptoms and LF82SK colonisation levels. In the group receiving the preventive treatment, DAI score on Day 10 was lower than that in the other two groups. It subsequently returned to background levels, and remained at this level for the next 15 days [ Figure 4B ]. In the group receiving the curative treatment on Day 10, DAI had decreased 4 days post treatment but to a lesser extent than in the control group, and it remained low for the next 11 days [ Figure 4B ]. Mean faecal levels of strain LF82SK from Day 7 to Day 25 remained stable in the control group [from 3.6 x 10 9 ± 2.2 x 10 9 to 3.6 x 10 8 ± 3.34 x 10 8 cfu/g] but decreased by 6.000 [from 4.8 x 10 9 ± 1.6 x 10 9 to 7.7 x 10 5 ± 1.1 x 10 6 cfu/g] and 43.000 [4.0 x 10 9 ± 1.4 x 10 9 to 9.3 x 10 4 ± 1.1 x 10 5 cfu/g] times, respectively, in the preventive and curative groups. Furthermore, these results were confirmed using molecular quantification of ileal and colonic sections collected on Day 25 [ Figure 4C , D]. A single bacteriophage application therefore successfully decreased colitis symptoms and mediated the long-term decolonisation of the GIT with AIEC.
Bacteriophages actively replicate on ileal biopsies from CD patients
In order to provide an evaluation of the potential of this cocktail to target AIEC strains in patients, we measured its replication in six CD patients' ileal biopsies spiked with strain LF82SK. Active replication of the cocktail was measured after 5 h from bacteriophage administration [mean n-fold replication 9. 
Discussion
Dysbiosis of the gut microbiota is now recognised as a hallmark of IBD. It leads to the overgrowth of enterobacteria, including E. coli strains from the AIEC group which are particularly predominant. 34 Antibiotic treatments have been proposed but expose CD patients to the risk of adverse events such as exacerbation of dysbiosis, with detrimental effects such as promotion of the growth of pathogenic strains or an increase in inflammation. Antibiotic-resistant bacteria may also be selected, decreasing the chances of a successful treatment outcome. Furthermore, the long-term antibiotic treatments with ciprofloxacin and metronidazole frequently used to treat CD are associated with a high risk of adverse effects resulting in treatment intolerance. Phage therapy is not only a specific way to target pathogens with a lower impact on microbiota than antibiotics, it can also provide a solution to the problem of antibiotic-resistant strains. 24, 25, 35, 36 In this study, we investigated the activity of a cocktail of three bacteriophages targeting AIEC strain LF82. The choice of these bacteriophages was guided to obtain the largest host range towards the E. Coli Reference [ECOR] collection which embraces the genetic diversity of E. coli genus, as AIEC strains do not belong to a particular genotype or serotype. A complementary strategy could consist of using a collection of characterised AIEC strains to implement this initial cocktail towards CD patients' strains. We showed ex vivo that each bacteriophage was able to replicate in the GIT. As in similar experiments performed previously with six bacteriophages infecting two different strains of E. coli, we found that each of the three LF82 bacteriophages replicated in gut sections. 25, 31 These three LF82-bacteriophages belong to the Myoviridae family of viruses, whereas the bacteriophages previously reported to have a lower performance belong to the Podoviridae and Siphoviridae families. However, we found that all nine bacteriophages tested ex vivo to date replicated strongly in the ileal section of the GIT, suggesting that this compartment does not restrict bacterial permissivity to bacteriophage infection, as also supported by the high level of bacteriophage cocktail replication in ileal biopsies of CD patients. On the other hand, in other mouse gut sections, bacteriophage replication was highly variable. Therefore, the biogeography of the GIT probably affects bacteriophage replication, possibly due to differences in bacterial physiology between different GIT sections which in addition display different mucus layers that are associated with specific microbiota. [37] [38] [39] [40] Also, recent evidence showed that some bacteriophages bind mucus, which could affect their persistence in the GIT. 41, 42 Using CEABAC10 mice, we showed that the cocktail of bacteriophages strongly decreased intestinal colonisation by strain LF82, suggesting that bacteriophages were able to reach the epithelial surface bearing the CEACAM6 receptor of strain LF82. This strong decrease was observed with both CEABAC10 and conventional mice in the absence and presence of antibiotic pressure, respectively. These reduced colonisation levels, obtained with a single application of the cocktail, were highly significant [relative to the control groups] and they persisted for at least 2 weeks, corresponding to the highest efficacy ever reported in experimental models of intestinal colonisation, perhaps because we used a cocktail of three Myoviridae. 25, 31, 43, 44 Thus, one of the key characteristics and advantages of bacteriophages over antibiotics, their ability to self-amplify and increase their own concentrations locally, translated directly into a decrease in the concentration of the target bacteria in the GIT. Self-limitation was also observed, as the number of bacteriophages decreased over time with decreasing levels of their target. In addition, we found that the decrease in AIEC levels mediated by bacteriophage treatment was accompanied by a decrease in colitis symptoms, a promising result for possible future clinical applications.
The safety of bacteriophages targeting intestinal pathogens is well documented for adults and infants, based on data for a clinical trial on diarrhoeal diseases in which no adverse events were reported. 23, 24, 45 This is not surprising as bacteriophages are the most abundant viruses present in the human GIT, being part of our natural microbiota, and are far more abundant than viruses infecting eukaryotic cells. 46, 47 Recent virome studies on samples from IBD patients showed that the microbiota of these patients displayed an altered bacteriophage composition, raising questions about the possible role of these viruses in the disease. 48 Most of the bacteriophages detected were temperate [as opposed to virulent], suggesting a putative role in dynamic interactions between bacteria possibly leading to genetic exchanges. 49 The bacteriophages recommended for therapeutic applications, such as those reported here, are virulent and our experimental data support their use for targeting AIEC strains as part of a gentle approach to re-establishing eubiosis in CD patients, possibly extending the intervals between relapses. The funders had no role in study design, data collection and interpretation, nor the decision to submit the work for publication.
